Cover Image
市場調查報告書

醫藥品分析:Lynparza

Drug Overview: Lynparza

出版商 Datamonitor Healthcare 商品編碼 604000
出版日期 內容資訊 英文 61 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
醫藥品分析:Lynparza Drug Overview: Lynparza
出版日期: 2018年01月18日 內容資訊: 英文 61 Pages
簡介

本報告提供Lynparza調查分析,產品簡介相關的系統性資訊。

產品簡介

  • Lynparza :前列腺癌症
  • Lynparza :卵巢癌症
  • Lynparza :三陰性乳癌
  • Lynparza :胰臟癌症
  • Lynparza :乳癌 (HR+/HER2-)

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: DMKC0126690

Drug Overview

Lynparza (olaparib; AstraZeneca/Merck & Co) is a small molecule poly (ADP-ribose) polymerase (PARP) inhibitor for the treatment of BRCA mutation-positive (BRCAm+) ovarian cancer. The PARP enzyme plays an essential role in DNA repair mechanisms and homologous recombination events. PARP inhibitors act by directly blocking enzymatic activity, or by causing PARP to accumulate on DNA (PARP trapping), which results in DNA replication inhibition and cell death. Tumor cells with BRCA1/2 gene mutations are dependent on PARP for DNA damage repair, and PARP inhibition selectively kills BRCA1- or BRCA2-deficient cells. As DNA repair is inhibited by PARP inhibitors, they are often sequenced after a cytotoxic chemotherapy which works by damaging DNA.

BRCA1 and BRCA2 encode proteins that are required for DNA damage repair. Inherited mutations in these genes have been linked to a predisposition towards the development of breast and ovarian cancers. In the US, it has been estimated that inherited BRCA1 and BRCA2 mutations account for 5-10% of breast cancers and 10-15% of ovarian cancers among white women.

The drug is also being developed by AstraZeneca and Merck & Co for the treatment of prostate cancer.

TABLE OF CONTENTS

5 Product Profiles

5 Lynparza : Prostate cancer

17 Lynparza : Ovarian cancer

36 Lynparza : Breast cancer: triple-negative

45 Lynparza : Pancreatic cancer

52 Lynparza : Breast cancer: HR+/HER2-

LIST OF FIGURES

  • 10 Figure 1: Lynparza for prostate cancer - SWOT analysis
  • 11 Figure 2: Datamonitor Healthcare's drug assessment summary of Lynparza for prostate cancer
  • 12 Figure 3: Datamonitor Healthcare's drug assessment summary of Lynparza for prostate cancer
  • 14 Figure 4: Lynparza sales for prostate cancer across the US, Japan, and five major EU markets, by country, 2017-26
  • 28 Figure 5: Lynparza for ovarian cancer - SWOT analysis
  • 29 Figure 6: Datamonitor Healthcare's drug assessment of Lynparza for ovarian cancer
  • 30 Figure 7: Datamonitor Healthcare's drug assessment of Lynparza for ovarian cancer
  • 40 Figure 8: Lynparza for triple-negative breast cancer - SWOT analysis
  • 41 Figure 9: Datamonitor Healthcare's drug assessment summary of Lynparza for triple-negative breast cancer
  • 42 Figure 10: Datamonitor Healthcare's drug assessment summary of Lynparza for triple-negative breast cancer
  • 48 Figure 11: Lynparza for pancreatic cancer - SWOT analysis
  • 49 Figure 12: Datamonitor Healthcare's drug assessment summary of Lynparza in pancreatic cancer
  • 50 Figure 13: Datamonitor Healthcare's drug assessment summary of Lynparza in pancreatic cancer
  • 56 Figure 14: Lynparza for HR+/HER2- breast cancer - SWOT analysis
  • 57 Figure 15: Datamonitor Healthcare's drug assessment summary of Lynparza in HR+/HER2- breast cancer
  • 58 Figure 16: Datamonitor Healthcare's drug assessment summary of Lynparza in HR+/HER2- breast cancer

LIST OF TABLES

  • 6 Table 1: Lynparza drug profile
  • 7 Table 2: Lynparza Phase III trial in prostate cancer
  • 9 Table 3: Lynparza Phase II data in prostate cancer
  • 15 Table 4: Lynparza sales for prostate cancer across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • 18 Table 5: Lynparza drug profile
  • 20 Table 6: Lynparza pivotal trial data in ovarian cancer
  • 24 Table 7: Lynparza ongoing late-phase clinical trials in ovarian cancer
  • 27 Table 8: Overview of early-phase data for Lynparza in ovarian cancer
  • 37 Table 9: Lynparza drug profile
  • 38 Table 10: Lynparza Phase III trials in triple-negative breast cancer
  • 39 Table 11: Lynparza Phase II data in triple-negative breast cancer
  • 46 Table 12: Lynparza drug profile
  • 47 Table 13: Lynparza Phase III trials in pancreatic cancer
  • 53 Table 14: Lynparza drug profile
  • 54 Table 15: Lynparza Phase III trial in HR+/HER2- breast cancer
  • 55 Table 16: Lynparza Phase II data in HR+/HER2- breast cancer

 

Back to Top